Anixa Biosciences, Inc. announced that Jose Conejo-Garcia, M.D., Ph.D., co-inventor of the company's CAR-T technology, will deliver a keynote presentation at the South Carolina Clinical & Translational Research Institute 2026 Retreat focused on cell-based therapies. The presentation, scheduled for March 6, 2026, is expected to include discussion of Anixa's ongoing Phase 1 clinical trial of liraltagene autoleucel (lira-cel), an FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
The clinical trial is enrolling women with ovarian cancer who have progressed after at least two prior therapies. This therapy represents a novel approach in cancer treatment, using what the company describes as chimeric endocrine receptor-T cell (CER-T) technology. Unlike traditional CAR-T therapies that use antibody fragments, this technology leverages the natural ligand of the FSHR receptor, FSH, to bind to tumor cells.
Anixa's therapeutic portfolio includes this ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, a world leader in cancer immunotherapy treatments. The company's business model involves partnering with renowned research institutions throughout development stages, allowing for continuous examination of emerging technologies in complementary fields. More information about the company's approach can be found at https://www.anixa.com.
The company's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast cancer, ovarian cancer, and additional cancers including lung, colon, and prostate malignancies. These vaccines focus on immunizing against "retired" proteins found to be expressed in certain forms of cancer. Cleveland Clinic is entitled to royalties and other commercialization revenues from Anixa related to these vaccine technologies.
The announcement was distributed through BioMedWire, a specialized communications platform focusing on biotechnology and biomedical sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides various distribution services including access to wire solutions, article syndication to thousands of outlets, press release enhancement, and social media distribution. Additional information about the distribution platform is available at https://www.BioMedWire.com.
For business and technology leaders, this development highlights several important trends in the biotechnology sector. The keynote presentation at a major research retreat signals growing recognition of Anixa's innovative approach to cancer treatment. The company's focus on ovarian cancer addresses a significant unmet medical need, as recurrent ovarian cancer remains challenging to treat with existing therapies.
The implications extend beyond this specific therapy to the broader field of cell-based cancer treatments. Anixa's CER-T technology represents a differentiation from existing CAR-T approaches, potentially offering advantages in specificity and reduced side effects. The company's partnership model with leading research institutions like Moffitt Cancer Center and Cleveland Clinic demonstrates an efficient approach to biotechnology development, leveraging expertise across multiple organizations.
For the healthcare industry, successful development of these therapies could expand treatment options for various cancers, potentially improving patient outcomes and reducing healthcare costs associated with ineffective treatments. The timing of the presentation in 2026 suggests that clinical data from the Phase 1 trial will be available by then, providing valuable insights into the therapy's safety and efficacy profile.
